Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.